PDCD1 and neoplasm: Immune profiling studies comparing TIL and peripheral blood from patients with HNSCC demonstrated expression of OX40, as well as PD-1 and CTLA-4, on T cells isolated from the tumor compared to blood, suggesting that targeting these pathways independently or in combination may result in therapeutic advantages23.